drugset / Trial / NCT01546753

Walnut Oral Immunotherapy for Tree Nut Allergy

NCT01546753 ↗

Phase 1/2 Completed 22 enrolled University of Arkansas
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine if walnut oral immunotherapy can be used in participants allergic to tree nuts to reduce tree nut allergy and induce changes in the participant's immune system.

Timeline

Start
2012-04-27
Primary completion
2015-07-02
Completion
2020-07-02

Outcome

Met primary endpoint

registry analysis (superiority test); Walnut Protein Powder vs Oat Powder; p = 0.001; Wilcoxon (Mann-Whitney) NCT01546753 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Walnut Protein Powder Protein / enzyme biologic 1500 mg Oral

Indications

No indication recorded.